The combination of ATN-161 and 5-FU results in a notable reduction in tumor cell proliferation compared to both control and monotherapy (p<0.01). Furthermore, the combined treatment leads to a significant increase in apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas monotherapy does not increase the number of TUNEL-positive tumor cells. Following a 48-hour incubation period, ATN-161 treatment leads to a significant decrease in endothelial cell (EC) count (21% reduction) compared to control (p<0.03) [1]. ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, while showing no effect on proliferation. It reduces the number of cells migrating in response to VEGF in a dose-dependent manner, starting at 100 nM (P<0.001 vs. VEGF group)[2].
体内研究
Preliminary experiments conducted with α5β1-negative human colon cancer xenografts (HT29) demonstrate that ATN-161 treatment significantly decreases both tumor weight and vessel density [1].
Administration of ATN-161 following laser photocoagulation effectively suppresses choroidal neovascularization (CNV) leakage and neovascularization to a degree comparable to that of AF564 [2].
体外研究
The combination of ATN-161 and 5-FU results in a notable reduction in tumor cell proliferation compared to both control and monotherapy (p<0.01). Furthermore, the combined treatment leads to a significant increase in apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas monotherapy does not increase the number of TUNEL-positive tumor cells. Following a 48-hour incubation period, ATN-161 treatment leads to a significant decrease in endothelial cell (EC) count (21% reduction) compared to control (p<0.03) [1].
ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, while showing no effect on proliferation. It reduces the number of cells migrating in response to VEGF in a dose-dependent manner, starting at 100 nM (P<0.001 vs. VEGF group)[2].
搜索
